Chronic Myeloid Leukemia
Imatinib mesylate treats secondary malignancy with favorable outcome
Published in Cancer Weekly, July 18th, 2006
According to recent research from the United States, "Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies.
"Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported."
According to the authors, "We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively."
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-07-18)
More Articles from Cancer Weekly
- Head & Neck Cancer
Head and neck cancer-related tumor hypoxia detected by positron emission tomography - Oral Cancer
Oral cancer metastases detected by F-18-FDG PET/CT - Oropharyngeal Cancer
Oropharyngeal carcinoma patient quality of life influenced by gender - Prostate Cancer
Prostate cancer responded to synergistic effects of radiation and beta-lapachone - Acute Myeloid Leukemia
Acute myeloid leukemia prognosticated by size of FLT3 internal tandem duplication - Adrenocortical Cancer
Adrenocortical carcinoma outcome predicted by tumor grade, tumor stage, and surgical resection - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
